TY - JOUR
T1 - Essential Data Dimensions for prospective international data collection in Older Age Bipolar Disorder (OABD)
T2 - Recommendations from the GAGE-BD group
AU - Lavin, Paola
AU - Rej, Soham
AU - Olagunju, Andrew T
AU - Teixeira, Antonio L
AU - Dols, Annemieke
AU - Alda, Martin
AU - Almeida, Osvaldo P
AU - Altinbas, Kursat
AU - Balanzá-Martínez, Vicent
AU - Barbosa, Izabela G
AU - Blumberg, Hilary P
AU - Briggs, Farren
AU - Calkin, Cynthia
AU - Cassidy, Kristin
AU - Forester, Brent P
AU - Forlenza, Orestes V
AU - Hajek, Tomas
AU - Haarman, Barthomeus C M
AU - Jimenez, Esther
AU - Lafer, Beny
AU - Mulsant, Benoit
AU - Oluwaniyi, Stephen O
AU - Patrick, Regan
AU - Radua, Joaquim
AU - Schouws, Sigfried
AU - Sekhon, Harmehr
AU - Simhandl, Christian
AU - Soares, Jair C
AU - Tsai, Shang-Ying
AU - Vieta, Eduard
AU - Villa, Luca M
AU - Sajatovic, Martha
AU - Eyler, Lisa T
N1 - Funding Information:
Brent Forester has received research funding from the NIH, Biogen, Eisai, Rogers Family Foundation, and Spier Family Foundation; Consultant: Patina Health. Pharmacy & Therapeutics Committee: CVS Health, Assurex, Eli Lilly, and. He is also a consultant for Sunovion Pharmaceuticals, Inc., Eli Lilly, Biogen, INSYS therapeutics, and Liberty Mutual Inc. Martha Sajatovic: Research grants within past 3 years: Nuromate, Otsuka, International Society for Bipolar Disorders (ISBD), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Patient‐Centered Outcomes Research Institute (PCORI); Consultant: Alkermes, Otsuka, Sunovion, Janssen, Lundbeck, Clinical Education Alliance, Myriad, Health Analytics, Frontline Medical Communications. Royalties: Springer Press, Johns Hopkins University Press, Oxford Press, UpToDate Compensation for preparation of/participation in CME activities: American Physician's Institute, MCM Education, CMEology, Potomac Center for Medical Education, Global Medical Education, Creative Educational Concepts, Psychopharmacology Institute, Neurocrine. Harmehr Sekhon is supported by a CIHR fellowship, MITACS Fellowship, and AGE‐WELL Award. Soham Rej is a consultant for the Steering Committee for AbbVie in addition to shareholder of Alfred Health. Hilary Blumberg has consulted the Milken Institute. Eduard Vieta has received grants and served as a consultant, advisor, or CME speaker for the following entities: AB‐Biotics, AbbVie, Angelini, Biogen, Boehringer‐Ingelheim, Celon Pharma, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, GH Research, Glaxo‐Smith Kline, Janssen, Lundbeck, Milken Institute, Novartis, Orion Corporation, Organon, Otsuka, Sage, Sanofi‐Aventis, Sunovion, Takeda, and UpToDate, outside the submitted work. Vicent Balanzá‐Martínez has served as a consultant, advisor, or CME speaker over the last 3 years for the following companies: Angelini, Lundbeck, Nutrición Médica, and Otsuka, outside the submitted work. Regan Patrick receives salary support through the Rogers Family Foundation, Biogen, and NIH/NIA. The remaining authors have no conflicts of interest to declare.
Publisher Copyright:
© 2023 John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
PY - 2023/11
Y1 - 2023/11
N2 - BACKGROUND: By 2030, over 50% of individuals living with bipolar disorder (BD) are expected to be aged ≥ 50 years. However, older age bipolar disorder (OABD) remains understudied. There are limited large-scale prospectively collected data organized in key dimensions capable of addressing several fundamental questions about BD affecting this subgroup of patients.METHODS: We developed initial recommendations for the essential dimensions for OABD data collection, based on 1) a systematic review of measures used in OABD studies, 2) a Delphi consensus of international OABD experts, 3) experience with harmonizing OABD data in the Global Aging & Geriatric Experiments in Bipolar Disorder Database (GAGE-BD, n≥4,500 participants), and 4) critical feedback from 34 global experts in geriatric mental health.RESULTS: We identified 15 key dimensions and variables within each that are relevant for the investigation of OABD: 1) demographics, 2) core symptoms of depression and 3) mania, 4) cognition screening and subjective cognitive function, 5) elements for BD diagnosis, 6) descriptors of course of illness, 7) treatment, 8) suicidality , 9) current medication , 10) psychiatric comorbidity, 11) psychotic symptoms, 12) general medical comorbidities, 13) functioning , 14) family history, and 15) other. We also recommend particular instruments for capturing some of the dimensions and variables.CONCLUSION: The essential data dimensions we present should be of use to guide future international data collection in OABD and clinical practice. In the longer-term, we aim to establish a prospective consortium using this core set of dimensions and associated variables to answer research questions relevant to OABD.
AB - BACKGROUND: By 2030, over 50% of individuals living with bipolar disorder (BD) are expected to be aged ≥ 50 years. However, older age bipolar disorder (OABD) remains understudied. There are limited large-scale prospectively collected data organized in key dimensions capable of addressing several fundamental questions about BD affecting this subgroup of patients.METHODS: We developed initial recommendations for the essential dimensions for OABD data collection, based on 1) a systematic review of measures used in OABD studies, 2) a Delphi consensus of international OABD experts, 3) experience with harmonizing OABD data in the Global Aging & Geriatric Experiments in Bipolar Disorder Database (GAGE-BD, n≥4,500 participants), and 4) critical feedback from 34 global experts in geriatric mental health.RESULTS: We identified 15 key dimensions and variables within each that are relevant for the investigation of OABD: 1) demographics, 2) core symptoms of depression and 3) mania, 4) cognition screening and subjective cognitive function, 5) elements for BD diagnosis, 6) descriptors of course of illness, 7) treatment, 8) suicidality , 9) current medication , 10) psychiatric comorbidity, 11) psychotic symptoms, 12) general medical comorbidities, 13) functioning , 14) family history, and 15) other. We also recommend particular instruments for capturing some of the dimensions and variables.CONCLUSION: The essential data dimensions we present should be of use to guide future international data collection in OABD and clinical practice. In the longer-term, we aim to establish a prospective consortium using this core set of dimensions and associated variables to answer research questions relevant to OABD.
KW - international collaboration
KW - older age bipolar disorder
KW - prospective studies
UR - http://www.scopus.com/inward/record.url?scp=85150616135&partnerID=8YFLogxK
U2 - 10.1111/bdi.13312
DO - 10.1111/bdi.13312
M3 - Article
C2 - 36843436
SN - 1398-5647
VL - 25
SP - 554
EP - 563
JO - Bipolar Disorders
JF - Bipolar Disorders
IS - 7
ER -